The efficacy of IVIG in preventing GvHD has not been definitely demonstrated clinically. Using a xenogeneic model of GvHD in NOD/SCID/ccÀ (NSG) mice, we showed that weekly administration of IVIG significantly reduced the incidence and associated mortality of GvHD to a degree similar to CsA. Unlike CsA and OKT3, IVIG were not associated with inhibition of human T-cell proliferation in mice. Instead, IVIG significantly inhibited the secretion of human IL-17, IL-2, IFN-c and IL-15 suggesting that IVIG prevented GvHD by immunomodulation. Furthermore, the pattern of modification of the human cytokine storm differed from that observed with CsA and OKT3. Finally, in a humanized mouse model of immune reconstitution, in which NSG mice were engrafted with human CD34 þ stem cells, IVIG transiently inhibited B-cell reconstitution, whereas peripheral T-cell reconstitution and thymopoiesis were unaffected. Together these in vivo data raise debate related to the appropriateness of IVIG in GvHD prophylaxis. In addition, this model provides an opportunity to further elucidate the precise mechanism(s) by which IVIG inhibit GvHD.
Introduction
GvHD is a major complication of allogeneic HSCT. [1] [2] [3] [4] Clinically significant acute GvHD may occur in 9-50% of patients who receive an allogeneic HLA-matched HSCT, even when intense immunoprophylaxis is used. 4 As the incidence of GvHD may approach 100% in the absence of prophylaxis, 5, 6 GvHD prophylaxis is essential in all patients undergoing allogeneic HSCT. 7 This prophylaxis is usually provided by means of immunosuppressive drugs, mainly steroids, CsA and MTX, usually used in combination. [8] [9] [10] Albeit effective in GvHD prophylaxis by reducing its incidence, these agents impair the quality and kinetics of immune reconstitution. These effects enhance the risk of morbidity and mortality, mainly due to infection and relapse in the context of HSCT performed for malignancy. IVIG have been shown to be an effective immunomodulator in many autoimmune diseases 11 and to prevent infections in primary immunodeficiencies. Thus, it was tempting to hypothesize that IVIG might be very attractive in the context of allogeneic HSCT by inhibiting GvHD and preventing infectious diseases. This is supported by the current status of IVIG as an approved therapy for GvHD prophylaxis, although many authors question their utility. 12 On one hand, Sullivan et al. 13 showed in a randomized trial that weekly IVIG reduced the cumulative incidence of acute GvHD and that this effect was significant in patients receiving HLA-identical HSCT. Also, in patients older than 20 years receiving HLA-identical HSCT, the incidence of non-relapse mortality was significantly less in patients receiving IVIG. On the other hand, many studies [14] [15] [16] [17] [18] have failed to demonstrate that IVIG significantly reduced the incidence of acute GvHD or overall mortality. In addition, Sullivan et al. 17 showed that extending IVIG treatment for longer than 3 months post-HSCT was associated with a significantly delayed recovery of humoral immunity and a significant increase in infections while overall and non-relapse mortality did not differ. Given the impossibility of conducting a blinded-randomized clinical trial and the high heterogeneity among patients (age, disease, conditioning regimen, prophylaxis treatments and donor source), a relevant animal model is the only way to determine the role of IVIG in GvHD reduction. We developed a xenogeneic model of GvHD and a humanized mouse model of human immune reconstitution following HSCT and both used NOD/SCID/gcÀ (NSG) mice. We used these models to determine the impact of IVIG on reducing GvHD and impairing thymic and peripheral immune reconstitution.
Materials and methods

Mice
NOD/LtSz-scidIL2rg
À/À mice were obtained from the Jackson Laboratory (Bar Harbor, ME, USA) and bred in the animal care facility at the CHU Sainte-Justine Research Centre. NOD/LtSz-scidIL2rg À/À were also generated in house by backcrossing NOD.CB17-Prkdc scid and C.12954-IL2rg tm1WjL /J mice as described by Shultz et al. 19 All mice (hereafter called NSG mice) were equally used for the purpose of this study. Mice were housed under specific pathogen-free conditions in sterile ventilated racks. All procedures were previously approved by the institutional committee for Good Laboratory Practices for Animal Research (GLPAR), as per our research protocols (SST08-77 and SST09-22). Irradiated mice were given 0.08 mg/mL ciprofloxacin (Sandoz, Boucherville, Canada) in their drinking water.
Xenogeneic model of GvHD
Human PBMC (huPBMC) collected from leukapheresis from three healthy donors following informed written consent was isolated by Ficoll-Paque PLUS (GE Healthcare Bio-Sciences AB, Uppsala, Sweden). Following sublethal 3 Gy irradiation, 7-9 week-old mice were injected intraperitoneally (i.p.) with 10 7 huPBMC at day 0 and treated with either PBS or IVIG (Gamunex 50 mg/mouse) (Talecris Biotherapeutics, Research Triangle Park, NC, USA) once a week from day À1 to day þ 42. Mice treated with CsA (0.375 mg/mouse) were injected i.p. daily from day 0 to day þ 23 20 and mice treated with OKT3 (0.05 mg/mouse) were injected i.p. on days þ 1, þ 3 and þ 5.
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Assessment of GvHD
Mice were evaluated in a blinded fashion every other day using a GvHD assessment scale. The GvHD assessment scale, inspired by the grading system established by Cooke et al., 22 refers to weight loss, general appearance of the fur and mobility. GvHD diagnosis was given to a mouse upon a 10% weight loss, appearance of ruffled fur and limited mobility. Survival was also noted for each group. As requested by our GLPAR committee, mice were killed when clinical endpoints were reached (weight loss 420% and appearance of either limited mobility or disruption of general appearance of the mice). The liver, gut and skin were collected from the euthanized mice and analyzed by a pathologist for GvHD lesions. A volume of 100 mL of peripheral blood was drawn weekly from the saphenous vein. Circulating cells were analyzed by flow cytometry to determine lymphocyte populations and plasma was collected to determine human cytokine concentrations.
Humanized mouse model of human immune reconstitution Human CD34 þ (hCD34 þ ) hematopoietic stem cells were isolated from cord blood units using CD34 þ magnetic beads (MACS Miltenyi Biotec, Auburn, AL, USA). Cord blood units were obtained from the CHU Sainte-Justine Research Cord Blood Bank following approval by the ethics committee. Mice were injected intravenously with 10 5 hCD34 þ cells following 3 Gy sub-lethal irradiation and treated with either PBS or IVIG (Gamunex 50 mg/mouse) 23, 24 once a week from day À1 until the end of the experiment. Engraftment and immune reconstitution were assessed weekly on blood samples by flow cytometry. Upon killing of the mice, the thymi were analyzed by flow cytometry.
Flow cytometry
Human and murine cell populations in peripheral blood samples collected weekly from xeno-GvHD and from human immune reconstituted mice were analyzed by flow cytometry. Upon killing of the reconstituted mice, thymi were collected and analyzed. FITC anti-mouse CD45, FITC anti-human CD4, FITC anti-human CD14, PE antimouse CD45, PE anti-human CD8, PE anti-human CD19, PE anti-human CD45RA, PE anti-human CD56, APC anti-human CD45, APC anti-human CD45RO, APC-Cy7 anti-human CD3 and APC-Cy7 anti-human CD45 antibodies (all purchased from BD Biosciences, Mississauga, Canada) were used to identify cell populations, along with 7-AAD for dead cell discrimination (BD Biosciences). CountBright beads were added before FACS acquisition to determine the absolute number of cells in each sample (Invitrogen, Burlington, Canada). Samples were acquired on a FACSAria flow cytometer and analyzed using the FACSDiva software (BD Bioscience).
Histology
Organs were frozen in OCT cubes, fixed in 10% formaldehyde, embedded in paraffin wax and oriented for histological analysis. Sections were stained with hematoxylin and eosin. Specimens were assessed by a pathologist.
Cytokine concentration
The concentration of human IL-2, IL-4, IL-6, IL-8, IL-10, IL-15, IL-17, TNF-a, and IFN-g were determined in 30 mL of mice plasma using a customized Bio-Plex Pro Human Cytokine 9-plex Assay (Bio-Rad Laboratories, Hercules, CA, USA). The experiments were conducted according to the manufacturer's recommendation and results were analyzed on a CS 1000 Autoplex Analyzer (Perkin Elmer Inc., Waltham, USA).
Human IgG concentration
The concentration of human IgG was determined in plasma of mice using a human IgG ELISA kit, as per the manufacturer's instructions (Bethyl Laboratories, Inc., Montgomery, AL, USA).
Statistics
Results were analyzed using GraphPad Prism 5.0 (GraphPad Softwares Inc., La Jolla, CA, USA). Survival statistics were determined using the Mantel-Cox (log-rank) test, which was stratified in time when needed. Elsewhere, Student's t-test, 2-by-2 Fisher's exact test with Bonferroni's correction and non-parametric one-way analysis of variance (Kruskal-Wallis) with Dunn's Multiple Comparison Test were used. Taking into account the post-test corrections, the threshold for significance was set at Pp0.05.
Results
IVIG reduced mortality in our xenogeneic GvHD model
To test whether IVIG could inhibit GvHD, we used a xenogeneic model of GvHD that consists of injecting huPBMC into sub-lethally irradiated NSG mice. 25, 26 As shown in Figure 1 , almost all control mice injected with 10 7 huPBMCs and PBS died within a period of 50 days. Histopathology performed at the time of killing showed severe characteristic lesions of GvHD with infiltrating human T-cells and biliary lesions (Figure 2 ), confirming that mice died from GvHD. Upon weekly IVIG treatment, GvHD-related mortality was both attenuated and delayed compared with PBS control mice (Po0.05, Figure 1 ). We also tested whether OKT3 and CsA could inhibit GvHD in this model. CsA is a key drug used in GvHD prophylaxis in humans [27] [28] [29] [30] and OKT3 is used for steroid-refractory GvHD. [31] [32] [33] [34] [35] [36] We showed that OKT3 and CsA significantly prevented GvHD-related mortality ( Figure 1 ), with a greater efficacy for OKT3. CsA was not significantly better than IVIG in preventing mortality (P ¼ 0.681), although as expected, there was evidence of superior efficacy of OKT3 over IVIG (P ¼ 0.009).
IVIG reduced the incidence of GvHD
As shown in Figure 3 , PBS-treated mice had a significantly greater incidence of GvHD than IVIG-treated mice, suggesting that IVIG prevented mortality by inhibiting GvHD. Also, CsA and OKT3 both significantly reduced the incidence of GvHD as compared with the PBS control group. We showed that CsA was not more efficient than IVIG in preventing GvHD whereas OKT3 was the best treatment to reduce the incidence of GvHD ( Figure 3 ). As an additional control group, 10 mice were injected i.p. weekly with the IVIG vehicle (200 mM glycine) and displayed the same mortality and GvHD incidence as the PBS control group (not shown).
The plasma concentration of human IgG in IVIG treated mice was 13 mg/mL (not shown). This is within the range of what is observed in patients treated with IVIG for GvHD 37 and to that reported by Siragam et al. 23 in their model of prevention of immune thrombocytopenia in mice. These reports validate that the IVIG dose in our protocol is relevant to clinical and experimental practice.
IVIG did not reduce human T-cell proliferation in mice
The percentage of human CD45 þ (hCD45 þ ) cells (determined by the ratio of human CD45 þ cells/human þ murine CD45 þ cells), assessed weekly in peripheral blood, was not modified by IVIG (Figure 4a ). Over 90% of hCD45 þ cells were CD3 þ T-cells in both groups (not shown), as observed by others in the same model. 25 As the ratio of hCD45 þ cells depends largely on murine CD45 þ cells, we quantified the absolute number of circulating human T-cells and showed that IVIG did not induce a reduction of T-cells in peripheral blood (Figure 4b ) or modify the ratio of CD4 þ and CD8 þ cells (not shown). As expected, both CsA and OKT3 induced a significant decrease of both the ratio of hCD45 þ cells and the absolute number of hCD3 þ cells in blood when compared with PBS and IVIG ( Figure 4 ). These results suggest that IVIG do not inhibit the proliferation of human T-cells in mice and support the hypothesis that IVIG reduce GvHD via immunomodulatory actions, as suggested by other authors.
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Determination of human plasma cytokine concentration We found a strong increase of IFN-g, IL-17 and IL-2, and a moderate increase of IL-6, IL-8, IL-10 and IL-15 in PBStreated mice when compared with baseline levels (set as levels before huPBMC injection). This confirmed the generation of a human cytokine storm in our xenogeneic GvHD model. Notably, we observed very low levels of TNF-a, and no IL-4 increase. IVIG treatment induced a significant reduction of IL-2 at day 14, IFN-g at day 7, IL-15 at day 14 and a dramatic reduction of IL-17 from day 7 to day 21. There was also a trend for a decrease of IL-8 although this was NS ( Figure 5 ). As a control experiment, we verified that the addition of 13 mg/mL IVIG (as observed in plasma of IVIG-treated mice) did not modify the cytokine concentration detected by the BioPlex Assay (not shown). These results suggest that IVIG have an immunomodulatory effect that might contribute to reducing GvHD in our model. Both CsA and OKT3 induced a significant reduction of IL-2 and IL-8 and a dramatic decrease of IFN-g. Also, CsA induced a significant reduction of IL-15 and IL-17 whereas OKT3 induced a significant reduction of IL-10. By comparing IVIG to CsA and OKT-3, we showed that the levels of IL-17 were significantly lower in IVIG-treated mice whereas the levels of IFN-g and IL-10 were significantly lower in CsA-and OKT3-treated mice. Taken together, these results suggest that IVIG treatment works by different mechanisms than OKT3 and CsA for both CD3 þ T-cell proliferation and cytokine secretion.
Effect of IVIG on human immune reconstitution
As it has been suggested that IVIG inhibit immune reconstitution, 17 we evaluated the effect of IVIG on immune reconstitution in a humanized mouse model of cord blood transplantation. Sub-lethally irradiated NSG mice were injected with human cord blood CD34 þ cells and mice were treated weekly with either PBS (n ¼ 4) or IVIG (n ¼ 5) from week 1 and until killing. Blood was drawn weekly to study the appearance of circulating human cells. As seen in Figure 6a , IVIG-treated mice showed a delayed engraftment of human CD45 þ cells for the first 56 days following hCD34 þ cell injection when compared with PBS-treated mice (Po0.05). To determine which cell populations were targeted by IVIG, we evaluated the relative percentage of all major cell populations (T, B, NK and monocytes) in the blood. Our results show that the kinetics of appearance of all analyzed human cell populations were the same in PBS-and IVIG-treated mice, except for the B-cell population (Figure 6b ). The appearance of peripheral human B-cells mirrored almost exactly the appearance of hCD45 þ cells. IVIG had no negative impact on the appearance of T-cells. Finally, T-cells were detected in peripheral blood by day 84 post transplantation in both groups with the same kinetics (Figure 6c ). When mice reached limit points and had to be killed (average time of killing was 27.9 and 28.2 weeks post-injection in the PBSand IVIG-treated groups, respectively), thymi were harvested and analyzed by flow cytometry. PBS-and IVIG-treated mice showed no significant difference in the percentage of human CD45 þ cells (Figure 7a ) or in its T-cell subsets, namely double positive (CD4
þ and CD45RA þ cells (Figure 7c ). These results suggest that IVIG did not affect the kinetics of thymopoiesis in this humanized mouse model. We also tested the effect of CsA and OKT3 on human immune reconstitution in our humanized mouse model. NSG mice injected with -- þ cells were treated with CsA (daily from day 0 until killing at day 42) or with OKT3 (weekly from day 0 until killing at day 42). As shown in Figure 8 , CsA and OKT3 did not modify the engraftment of hCD45 þ cells in blood. Nevertheless, we showed at killing that CsA reduced significantly the number of hCD45 þ cells in the thymus. The same trend, although NS, was observed in OKT3-treated mice. Taken together, these results suggest that IVIG delayed leukocyte engraftment of human CD45 þ cells by its negative effect on B-cell reconstitution in the first 2 months of treatment. Moreover, IVIG did not affect monocyte, NK cell or T-cell reconstitution and did not influence thymopoiesis.
Discussion
Despite its approval by the FDA for reducing infections and preventing GvHD complications in BMT, the utility of IVIG in preventing GvHD is still a matter of debate. 12 Although some studies show that IVIG reduce GvHD and mortality, many others fail to demonstrate the same effect. [14] [15] [16] [17] [18] As reviewed by Sokos et al., 12 IVIG were shown to be efficient in reducing GvHD in only three 13, 44, 45 of eight studies [13] [14] [15] [16] [17] [18] 44, 45 that together comprised of 2507 patients. Determining the true effect of IVIG in these clinical studies is a key challenge as it is difficult to derive quality data from comparisons of heterogenous stages of pathology and treatment regimens. In this work, we showed that weekly treatments with IVIG monotherapy induced a significant reduction of the incidence of GvHD and its related mortality in a xenograft mouse model. To our knowledge, this is the first in vivo demonstration of the efficacy of IVIG alone for prevention of GvHD. Our model also allowed the comparison between IVIG, OKT3 and CsA, an approach that is absolutely impossible in clinical setting for obvious ethical reasons. CsA is a calcineurin inhibitor that inhibits T-cell activation and proliferation 46 by preventing or blocking the synthesis of many cytokines, including IL-2 and IFN-g. [47] [48] [49] [50] OKT3 is a MoAb that directly reacts with the e-chain of the CD3 receptor on the TCR, initiating its clearance from the membrane surface, which leads to the silencing of T-cell allo-reactivity by inducing apoptosis. 36, 51 We showed that OKT3 and CsA reduced the incidence of GvHD by up to 60% and also decreased related mortality in NSG mice. These results are relevant from a clinical perspective as OKT3 is usually used for refractory GvHD. [31] [32] [33] [34] [35] [36] and despite first-line prophylaxis usually consisting of CsA and MTX, GvHD still occurs in 10-50% of patients depending on the HLA disparity between host and donor. 29, 52 Although CsA is considered a cornerstone in GvHD prophylaxis, we showed that its reduction of GvHD-related mortality was comparable to that observed by IVIG in our model. In a clinical setting, IVIG are used with CsA and other immunosuppressive drugs, although in our model IVIG and CsA were used alone. This likely explains why IVIG monotherapy prevented GvHD in our model although it is not considered to be efficient clinically in the context of polytherapy. Also, we have not tested whether the addition of IVIG to CsA could reduce the incidence of GvHD in our model. One could hypothesize that the immunosuppressive effect of CsA or other immunosuppressive drugs used in clinical setting overrides the effects of adjunct IVIG. Although our results cannot be taken as evidence-based medicine for the use of IVIG monotherapy in preventing GvHD, they strongly suggest that IVIG have an effect in vivo in preventing GvHD.
Literature suggests that IVIG could have a role in preventing GvHD by immunomodulation, although the exact mechanism(s) have never been precisely demonstrated. Our model provides the opportunity to study the mechanism(s) by which IVIG prevent GvHD. As patients often receive many immunosuppressive drugs simultaneously to prevent GvHD, it is very difficult to assess the individual role of a single drug. As expected, we found that after CsA or OKT3 treatment, the number of circulating human CD3
þ cells was reduced in NSG mice. Indeed CsA inhibits T-cell activation and proliferation 46-50 whereas OKT3 induces T-cell apoptosis. 36, 51 Unlike OKT3 and CsA, IVIG did not inhibit the proliferation of human T-cells. As inhibition of T-cell proliferation is one of the caveats of immunosuppression because it leads to the inhibition of the graft vs leukemia, this finding could have an impact on clinical practice. Many studies showed that IVIG inhibit T-cell proliferation or induce apoptosis 42, 43, [53] [54] [55] [56] [57] whereas others failed to demonstrate any direct effect of IVIG on T-cells. 58, 59 Interestingly, studies showing an inhibition of T-cell proliferation or an induction of apoptosis were performed in vitro whereas studies that failed to demonstrate any direct effect on T-cell proliferation were performed in vivo. þ cord blood cells, mice treated by PBS (n ¼ 3) or IVIG (n ¼ 5) were killed and thymus cells were analyzed by flow cytometry to determine human cell populations. Data are expressed as percentage of (a) hCD45 inducing an expansion of regulatory T-cells. 58 We tested this hypothesis in our model and failed to detect regulatory T-cell expansion, both in the peripheral blood and spleen (not shown).
Our GvHD xenogeneic model allowed us to quantify human cytokines and to assess the impact of various treatments on their secretion. We showed that IVIG had a significant impact on the human cytokine storm, thereby strongly suggesting that the prevention of GvHD by IVIG in our model was due to immunomodulation rather than a nonspecific effect. Interestingly, the pattern of cytokine inhibition induced by IVIG was different from one observed with CsA or OKT3. As expected, given their mechanisms of action, 36, [46] [47] [48] [49] [50] [51] [60] [61] [62] CsA and OKT3 inhibited most cytokines and particularly pro-inflammatory Th1 (IFN-g and IL-2) . Of all the cytokines tested, secretion of IFN-g was the highest recorded in PBS-treated mice suggesting that the reduction of GvHD in CSA and OKT3 mice was related to its inhibition. The moderate inhibition of IFN-g in the IVIG-treated group as compared with the strong inhibition in the CsA-and OKT3-treated groups is consistent with the observation that human T-cell proliferation was inhibited by OKT3 and CsA and not by IVIG. The significant reduction of IL-15 and IL-17 secretion in CsA-treated mice is consistent with CsA's ability to suppress IL-15-mediated IL-17 production. 60 IVIG dramatically reduced the levels of IL-17 whereas OKT3 did not inhibit IL-17 secretion and CsA inhibited its secretion only at week 2. The role of IL-17-producing Thelper cells is increasingly being recognized in GvHD. [63] [64] [65] [66] [67] Tournadre et al. 68 recently showed by analyzing muscle biopsies of patients with inflammatory myopathies that IVIG could mediate their immunomodulation by acting on the Th17 pathway. One could speculate that IVIG exert their modulatory effect on GvHD by impairing the Th17 pathway, although more analysis on other Th17-family cytokines and on the nature of IL-17 secreting cells in our model will be required to confirm this hypothesis. Taken together, these results indicate that IVIG have the potential to significantly alter the cytokine storm observed in our GvHD model. We did not find any predictive factor for the efficacy of IVIG in preventing GvHD in our model. In particular, human T-cell counts and cytokine levels were not different in GvHD-free IVIG-treated mice compared with IVIG-treated mice that developed GvHD.
The kinetics and the quality of immune reconstitution are crucial for preventing morbidity and mortality following HSCT. [69] [70] [71] [72] IVIG are considered an immunomodulatory rather than an immunosuppressive drug and thus could be very useful following HSCT as they should not inhibit immune reconstitution. Nevertheless, it has never been demonstrated that IVIG do not inhibit immune reconstitution post-HSCT. In addition, Sullivan et al. have shown that extending IVIG treatment after 3 months post-HSCT was associated with a significantly delayed recovery of humoral immunity and a significant increase in the rate of infections without affecting overall and non-relapse mortality. 17 By injecting hCD34 þ cells in NSG mice, we observed a human immune reconstitution very similar to what is observed by others using the same mouse model. [73] [74] [75] [76] [77] This model does not mimic exactly what is usually observed after HSCT in a clinical setting, but is nevertheless considered the best animal model to study in vivo immune reconstitution induced by hCD34 þ cells. As for GvHD, this model also allows the study of a given treatment used alone. We showed that CsA significantly inhibited human thymopoiesis and a similar trend (although NS) was observed with OKT3. Using this model, we showed that peripheral T-cell reconstitution, as well as thymopoiesis, was not affected by IVIG. However, we demonstrated a transient delay in B-cell reconstitution for the first 49 days post-injection in the IVIG-treated mice. It was recently shown by Se´ı¨te´et al. 78 that IVIG reduced B-cell viability and promoted apoptosis of B-cells by binding to CD22. Our model should allow us to test this hypothesis and investigate the other potential mechanism(s) by which early B-cell reconstitution is affected by IVIG. As IVIG are used for Ig replacement in primary B-cell deficiencies, it is likely that this transient B-cell deficiency should not have any significant clinical impact and should not preclude their use in a clinical setting after HSCT.
Our data provides new in vivo evidence that IVIG monotherapy reduces mortality induced by GvHD in a xenogeneic model with an efficacy comparable to CsA. Unlike CsA, this biological effect was not associated with an inhibition of T-cell proliferation. Instead, it was accompanied by a profound modification of the cytokine storm associated to GvHD, suggesting an immunomodulatory role in vivo. We also showed in a humanized mouse model of immune reconstitution that IVIG did not inhibit T-cell reconstitution and thymopoiesis, but instead induced a transient delay in B-cell reconstitution. Although our models do not mimic exactly GvHD and immune reconstitution observed in clinical setting, our data obtained in vivo with human cells may argue for the use of IVIG in GvHD prophylaxis. In addition, our models should help us to better understand the mechanism(s) by which IVIG inhibit GvHD, without confounding interference from other immunosuppressive drugs.
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